Page 3 - Synlogic Inc News Today

Accord Financial 3Q Loss/Shr C$1.03; 3Q Rev C$19.4M; 3Q Adj Loss/Shr C$0.97 Almonty Industries 3Q Rev C$4.45M; 3Q Loss/Shr C$0.01 Canaccord Genuity 2Q Rev C$337.3M, Down 11% on Year; 2Q... -November 15, 2023 at 06:14 am EST - MarketScreener

Synlogic Achieves Research Milestone and Earns $2.5 Million Milestone Payment from Roche Collaboration Cambridge, Mass. November 7, 2023 - Synlogic, Inc. , a clinical-stage...

Amarin (NASDAQ:AMRN – Get Free Report) and Roche (OTCMKTS:RHHBY – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, profitability, earnings, dividends and valuation. Volatility and Risk Amarin has a beta of 1.87, indicating […]

Shares of Synlogic, Inc. (NASDAQ:SYBX – Get Free Report) crossed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $6.25 and traded as low as $2.22. Synlogic shares last traded at $2.22, with a volume of 11,978 shares traded. Wall Street Analysts Forecast Growth […]

/PRNewswire/ -- A latest research report [115+] pages with 360-Degree visibility, titled "Gout Therapeutics Market Share, Size, Trends, Industry Analysis...

Amarin (NASDAQ:AMRN – Get Free Report) and Roche (OTCMKTS:RHHBY – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, dividends, earnings, valuation and risk. Valuation and Earnings This table compares Amarin and Roche’s top-line […]

CAMBRIDGE, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious

SYBX | Complete Synlogic Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

CAMBRIDGE, Mass., Sept. 28, 2023 -- Synlogic, Inc. , a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious...

Gainers Bionomics Limited (NASDAQ: BNOX) shares jumped 308% to $4.00 after the company announced the ATTUNE trial met its primary endpoint showing BNC210 treatment led to a statistically significant reduction in total PTSD symptom severity at 12 weeks.